lifestyle.longislandreport.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Currax Pharmaceuticals LLC
New Peer-Reviewed Scientific Publication Establishes Rationale for Combination Pharmacotherapy in Achieving Durable Weight Management
April 9, 2026
Currax Expands Patient Access to FDA-Approved Obesity Treatment with PeekDirect™
April 1, 2026
CONTRAVE Given the Highest Recommendation by Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults with Overweight or Obesity
March 25, 2026
Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
November 4, 2025
/C O R R E C T I O N — Currax Pharmaceuticals LLC/
October 30, 2025
/C O R R E C T I O N from Source — Currax Pharmaceuticals LLC/
October 29, 2025
Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
October 28, 2025
Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown
October 27, 2025